Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Claritas President and CEO
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(74)
•••
Post by Whyme16on Jun 24, 2022 8:42am
248 Views
Post# 34779692

Claritas President and CEO

Claritas President and CEObob farrell is a CRIMINAL & CHARLATAN...

Even the website https://claritaspharma.com doesn't work any longer!!!!

He is a scumbag who has robbed investors out of millions of dollars and has not DELIVERED ON A SINGLE PROMISE made to us in the last 5 years!

HE HAS DEFRAUDED MANY SHAREHOLDERS and I don't understand why the regulators don't do anything to stop the theft by these kind of mo..er f..ers! HE IS A CRIMINAL.

THIS KIND OF ANIMAL BELONG TO JAIL....He has been living in his mansion with OUR MONEY calling it the "COMPANY HEADQUARTERS".  

This mo..er Fu..er ASSURED US that Reverse Split is the ONLY THING PREVENTING BIG INVESTORS from getting involved and F..ing SALZMAN was the 1st one to jump ship at 47 cents (i.e. the RS price) AND

we are now back at 3 CENTS!!! COMPLETION OF PHASE 1 DELAYED BY ONE YEAR.....AND NOW SUSPENDED!! NO COMMUNICATION WITH SHAREHOLDERS!

We paid MILLIONS for GVHD and he F..ing gift wrapped it to his buddies and now this PUPPET doing the very same thing with R107 and GIFTING it to SALZMAN!! HE IS A LIER AND CHEAT...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities